Janux Therapeutics (JANX) Operating Income (2020 - 2025)
Historic Operating Income for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$35.3 million.
- Janux Therapeutics' Operating Income rose 164.89% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 6785.09%. This contributed to the annual value of -$98.8 million for FY2024, which is 3544.58% down from last year.
- Latest data reveals that Janux Therapeutics reported Operating Income of -$35.3 million as of Q3 2025, which was up 164.89% from -$45.1 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Operating Income ranged from a high of -$2.3 million in Q1 2021 and a low of -$45.1 million during Q2 2025
- Over the past 5 years, Janux Therapeutics' median Operating Income value was -$18.0 million (recorded in 2022), while the average stood at -$20.4 million.
- Per our database at Business Quant, Janux Therapeutics' Operating Income crashed by 76807.32% in 2021 and then skyrocketed by 3338.15% in 2024.
- Quarter analysis of 5 years shows Janux Therapeutics' Operating Income stood at -$13.5 million in 2021, then tumbled by 35.4% to -$18.3 million in 2022, then grew by 11.66% to -$16.1 million in 2023, then crashed by 79.85% to -$29.0 million in 2024, then decreased by 21.46% to -$35.3 million in 2025.
- Its Operating Income stands at -$35.3 million for Q3 2025, versus -$45.1 million for Q2 2025 and -$34.9 million for Q1 2025.